A Feature from Patrick Branch, Partner, Tokyo Office Head, LEK Consulting. Japan’s improving macro environment continued ...

Japan-based Nxera Pharma announced that positive top-line results were obtained from a Phase III study conducted in South ...

People who take part in a clinical trial often have to undergo many tests and trial visits, and it involves a significant ...

The European Commission has granted marketing authorization for Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for ...

US biotech ImmunityBio has reported two ongoing complete remissions lasting seven and 15 months in patients with Waldenstrom ...

Global life sciences M&A spending hit $240 billion in 2025, up 81% from $130 billion in 2024, as large pharma groups leaned ...

Spanish privately-held pharma company entered into an agreement to acquire USA-based TerSera's Infusion Specialty Therapies ...

Global regulators have ushered in 2026 with a slate of drug approvals, policy shifts and collaborative initiatives, including ...

The recent UK–US policy developments are reshaping global pharmaceutical investment and launch strategies, as governments on ...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for Enhertu ...

Russia is facing a shortage of drugs which are used for the treatment of schizophrenia, psychosis, bipolar disorder, and ...

Danish drugmaker Novo Nordisk's oral Wegovy (semaglutide) has recorded impressive early sales in the USA, and investors have ...